Trial Profile
A Study to Evaluate the Changes in Levels of Biomarkers Associated With Adipocyte Function and Insulin and Glucagon Kinetics after Meal Tolerance Test (MTT) During Treatment With Dapagliflozin among Obese Type 2 Diabetes Mellitus Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Jun 2016
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Biomarker; Therapeutic Use
- 28 Jun 2016 New trial record
- 22 Jun 2016 Primary endpoint has been met. (HbA1c level at 12 weeks), as per results published in the Drugs in R and D.
- 22 Jun 2016 Results published in the Drugs in R and D